[ad_1]
Los Angeles, USA, July 1, 2021 (Global News Agency)- Carcinoid syndrome pipeline analysis report: current therapies, emerging drugs and treatment prospects
The carcinoid syndrome pipeline is currently in its infancy, with more than 5 drugs active in the pipeline.
DelveInsight’s “Carcinoid syndrome pipeline insight“The report provides about 5+ Company and 5+ Pipeline drugs in the carcinoid syndrome pipeline landscape. It includes a pipeline drug profile for carcinoid syndrome, including clinical and non-clinical stage products. It also includes the evaluation of the treatment of carcinoid syndrome by product type, stage, route of administration and molecular type, and further highlights inactive carcinoid syndrome pipeline products.
Some key points Carcinoid syndrome pipeline report
- Big companies such as Crinetics Pharmaceuticals, Esteive TherapeuticsAnd others are developing potential drug candidates to improve treatment options for carcinoid syndrome.
- Octreotide (Sanstatin) Injection is the mainstay of symptom management of carcinoid syndrome. Xermelo (telotriastat ethyl) Tablet binding Somatostatin analog (SSA) This therapy has been approved by the FDA for the treatment of adults with carcinoid syndrome.
- In May 2021, Crinetics Pharmaceuticals announced its financial results for the first quarter ended March 31, 2021, and provided company updates. Crinetics mentioned that it plans to advance paltusotine to phase II trials to treat carcinoid syndromes associated with neuroendocrine tumors.
Get an overview of the pipeline landscape@ Analysis of clinical trials of carcinoid syndrome
Carcinoid syndrome is a series of symptoms secondary to carcinoid. This disease can be seen in individuals with potentially carcinoid tumors that have spread to the liver. The treatment of carcinoid syndrome involves drugs that control the signs and symptoms. The standard treatment is to surgically remove the entire tumor and reduce any metastasis when possible.
Emerging drugs for carcinoid syndrome
- Flounder: Crinetics Pharmaceuticals
halibut It is a new, oral, selective, non-peptide somatostatin receptor type 2 (SST2) agonist designed to treat carcinoid syndrome, neuroendocrine tumors (NET) and acromegaly. Somatostatin It is a neuropeptide hormone that can widely prohibit the pituitary gland from secreting other hormones, including growth hormone or GH. It is designed as a once-daily option for patients with acromegaly and neuroendocrine tumors currently undergoing injection therapy. Incarnation Plan to advance Pat Sootin second stage A trial for the treatment of NET-related carcinoid syndrome in 2021.
- Eenterade: Endogenous Bioscience
NCT03722511: In December 2018, Entrinsic Bioscience initiated a prospective phase II study to evaluate how amino acid-based medical foods (Enterade) maintain the ability of the intestine to absorb and retain fluids, thereby reducing neuroendocrine tumors (NET) caused Diarrhea and/or carcinoid syndrome. The study is currently in the recruitment phase and is expected to be completed in August 2022, with a total of 30 participants.
For more information, please refer to the detailed report@ Carcinoid syndrome pipeline therapy
range Carcinoid syndrome pipeline drug insight
- Coverage: Worldwide
- Main participants: 5+ key participants
- Outstanding players: Crinetics Pharmaceuticals, Aquestive Therapeutics and many other companies.
- Overview of main drugs: 5+ products
- stage:
· Late treatment of carcinoid syndrome (Phase III)
·Medium treatment of carcinoid syndrome (Phase II)
· Early treatment of carcinoid syndrome (stage 1)
·Carcinoid syndrome preclinical stage and discovery candidates
· Suspended and inactive candidates
- Mechanism:
· Somatostatin receptor 2 agonist
· Growth hormone receptor agonists
- Molecule type:
·Stem Cell Therapy
· Small molecule
The full story on Benzinga.com
[ad_2]
Source link
